ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - ProKidney aims to transform the treatment landscape for patients with advanced chronic kidney disease, particularly those at high risk of kidney failure and potential dialysis [2][4] - The company's lead product, rilparencel, is positioned as a meaningful intervention to alter the progression of kidney disease towards failure [3] Market Context - There are over 3 million Americans currently suffering from advanced chronic kidney disease, with many facing a high risk of developing kidney failure in the coming years [4] - The majority of these patients will require dialysis, while a fortunate few may receive kidney transplants, highlighting the urgent need for effective treatment options [4]